Androgens and cardiovascular risk;Androgene und kardiovaskul ä res Risiko

LaboratoriumsMedizin

Volumn 36, Issue 4, 2012, Pages 217-225

  Lerchbaum, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Androgens; Cardiovascular risk; Hyperandrogenemia; Hypogonadism

Indexed keywords

ANDROGEN; FAT; TESTOSTERONE;

AGING; ARTICLE; BONE MASS; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DYSLIPIDEMIA; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; HYPOGONADISM; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; MORTALITY; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE;

EID: 84869466704     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labmed-2011-0028     Document Type: Article

References (82)

1. Griffin JE, Wilson JD. Metabolic control and disease, 8th ed. Saunders, Philadelphia, 1980.
2. Vermeulen A, Verdonck L. Studies on the binding of testosterone to human plasma. Steroids 1968;11:609-35.
3. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76. (Pubitemid 41428540)
4. Araujo AB, Esche GR, Kupelian V, O' Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen defi ciency in men. J Clin Endocrinol Metab 2007;92:4241-7. (Pubitemid 350074738)
5. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, et al., European Male Aging Study Group. Hypothalamic-pituitarytesticular axis disruptions in older men are differentially linked to age and modifi able risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008;93:2737-45. (Pubitemid 352008544)
6. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31. (Pubitemid 32207487)
7. Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol 2005;152:501-13. (Pubitemid 40575794)
8. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977;45:1211-9. (Pubitemid 8253447)
9. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999;84:4677-94.
10. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al., EMAS Group. Identifi cation of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
11. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al., Task Force, Endocrine Society. Testosterone therapy in men with androgen defi ciency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.
12. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278-81. (Pubitemid 13055125)
13. Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone defi ciency: III. Cardiovascular disease. J Androl 2009;30:477-94.
14. Pugh PJ, Jones RD, Jones TH, Channer KS. Heart failure as an infl ammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail 2002;4:673-80. (Pubitemid 35403074)
15. Wehr E, Pilz S, Boehm BO, März W, Grammer T, Obermayer-Pietsch B. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 2011;13:482-8.
16. Wehr E, Pilz S, Boehm BO, März W, Grammer TB, Obermayer-Pietsch B. Sex steroids and mortality in men referred for coronary angiography. Clin Endocrinol 2010;73:613-21.
17. Jankowska EA, Drohomirecka A, Ponikowska B, Witkowska A, Lopuszanska M, Szklarska A, et al. Defi ciencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. Eur J Heart Fail 2010;12:966-73.
18. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, et al. Anabolic defi ciency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829-37. (Pubitemid 44673358)
19. Haring R, Völzke H, Steveling A, Krebs A, Felix SB, Schöfl C, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1494-501.
20. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701. (Pubitemid 350291241)
21. Platz E. Low testosterone and risk of premature death in older men: analytical and preanalytical issues in measuring circulating testosterone. Clin Chem 2008;54:1110-2. (Pubitemid 352009685)
22. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5. (Pubitemid 44232378)
23. Saad F, Gooren L. The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol 2009;114:40-3.
24. Golden KL, Marsh JD, Jiang Y. Testosterone regulates mRNA levels of calcium regulatory proteins in cardiac myocytes. Horm Metab Res 2004;36:197-202. (Pubitemid 38626405)
25. Sacca L. Heart failure as a multiple hormonal defi ciency syndrome. Circ Heart Fail 2009;2:151-6.
26. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Ferlin A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 2006;91:4599-602. (Pubitemid 44833444)
27. Foresta C, Zuccarello D, De Toni L, Garolla A, Caretta N, Ferlin A. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf) 2008;68:284-9.
28. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, et al. Hormonal profi le in patients with congestive heart failure. Int J Cardiol 2003;87:179-83. (Pubitemid 36135974)
29. Lerchbaum E, Pilz S, Grammer TB, Boehm BO, März W, Obermayer-Pietsch B. High estradiol levels are associated with increased mortality in older men referred to coronary angiography. Exp Clin Endocrinol Diabetes 2011;119:490-6.
30. Wehr E, Pilz S, Boehm BO, März W, Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol 2010;73:243-8.
31. Lee DM, Tajar A, Pye SR, Boonen S, Vanderschueren D, Bouillon R, et al., the EMAS study group. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol 2012;166:77-85.
32. Nimptsch K, Platz EA, Willett WC, Giovannucci E. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf) 2012;77:106-12
33. Pilz S, Frisch S, Koertke H, Kuhn J, Dreier J, Obermayer-Pietsch B, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 2011;43:223-5.
34. Lerchbaum E, Pilz S, Boehm BO, Grammer TB, Obermayer-Pietsch B, März W. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clin Endocrinol (Oxf) 2012:doi: 10.1111/j.1365-2265.2012.04371.
35. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al.. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75.
36. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.
37. Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008;101:618-24. (Pubitemid 351625084)
38. Malkin CJ, Pug hPJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64. (Pubitemid 41785933)
39. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and barorefl ex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27.
40. Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:265-93. (Pubitemid 29242714)
41. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038-49.
42. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
43. Wehr E, Schweighofer N, Möller R, Giuliani A, Pieber TR, Obermayer-Pietsch B. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 2010;59:575-80.
44. Graupp M, Wehr E, Schweighofer M, Pieber TR, Obermayer-Pietsch B. Association of genetic variants in the two isoforms of the 5γ-Reductase SRD5A1 and SRD5A2 in lean patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;157:175-9.
45. Lerchbaum E, Giuliani A, Gruber H, Pieber TR, Obermayer-Pietsch B. Adult-type hypolactasia and calcium intake in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012: doi: 10.1111/j.1365-2265.2012.04334.x.
46. Schweighofer N, Lerchbaum E, Trummer O, Schwetz V, Pilz S, Pieber TR, et al. Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome. Gene 2012;504:133-9.
47. Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D defi ciency in polycystic ovary syndrome. Eur J Endocrinol 2011;164: 741-9.
48. Lerchbaum E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B. Susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21, and 9q33.3 in a cohort of Caucasian women. Horm Metab Res 2011;43:743-7.
49. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genomewide association study identifi es susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2010;43:55-9.
50. Wehr E, Möller R, Horejsi R, Giuliani A, Kopera D, Schweighofer N, et al. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. Wien Klin Wochenschr 2009;121:262-9.
51. Lerchbaum E, Gruber HJ, Schwetz V, Giuliani A, Möller R, Pieber TR, et al. Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol 2011;165:935-43.
52. Wehr E, Gruber HJ, Giuliani A, Möller A, Pieber TR, Obermayer-Pietsch B. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab 2011;96:E986-90.
53. Wehr E, Pilz S, Boehm BO, März W, Obermayer-Pietsch B. The lipid accumulation product is associated with increased mortality in normal weight postmenopausal women. Obesity (Silver Spring) 2011;19:1873-80.
54. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-61.
55. de Groot PC DO, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the infl uence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011;17:495-500.
56. Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest 2007;30:111-6. (Pubitemid 46614441)
57. Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females. Diabetes 1991;40:693-700.
58. Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 2009;91:1848-52.
59. Lerchbaum E, Schwetz V, Giuliani A, Pieber TR, Obermayer-Pietsch B. Opposing effects of DHEAS and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil Steril 2012:in press.
60. Yamashita R, Saito T, Satoh S, Aoki K, Kaburagi Y, Sekihara H. Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocr J 2005;52:727-33. (Pubitemid 43104677)
61. Farah-Eways L, Reyna R, Knochenhauer ES, Bartolucci AA, Azziz R. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil Steril 2004;81:120-5. (Pubitemid 38058336)
62. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defi - ning polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237-45. (Pubitemid 44833391)
63. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009;161:575-82.
64. Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in PCOS women-a pilot study. J Endocrinol Invest 2011;34: 757-63.
65. Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab 2011;96:623-31.
66. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73: 724-9. (Pubitemid 30154110)
67. Wehr E, Pilz S, Boehm BO, Grammer TB, März W, Obermayer-Pietsch B. Low free testosterone levels are associated with allcause and cardiovascular mortality in postmenopausal diabetic women. Diabetes Care 2011;34:1771-7.
68. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009;361:1152-63.
69. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J 2006;332:73-8.
70. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009;18:169-76.
71. Bernini GP, Sgro' M, Moretti A, Argenio GF, Barlascini CO, Cristofani R, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 1999;84:2008-12. (Pubitemid 30647026)
72. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur J Endocrinol 2007;156:687-93. (Pubitemid 46952539)
73. Ouyang P, Vaidya D, Dobs A, Golden SH, Szklo M, Heckbert SR, et al. Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2009;204:255-61.
74. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Br Med J 1995;311:1193-6.
75. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276-84. (Pubitemid 351519721)
76. Sievers C, Klotsche J, Pieper L, Schneider HJ, März W, Wittchen HU, et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol 2010;163:699-708.
77. Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab 2010;95:740-7.
78. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, et al., Princeton. Female androgen insuffi ciency: the Princeton consensus statement on defi nition, classifi cation, and assessment. Fertil Steril 2002;77:660-5. (Pubitemid 34275339)
79. Studd J, Schwenkhagen A. The historical response to female sexuality. Maturitas 2009;63:107-11.
80. Martin-Du Pan R. Androgen defi ciency in women: indication and risks of testosterone or DHEA treatment. Rev Med Suisse 2007;3:792-6.
81. Miller KK, Biller BM, Beauregard C, Lipman JG, Jones J, Schoenfeld D, et al. Effects of testosterone replacement in androgen-defi cient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2006;91:1683-90.
82. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. J Sex Med 2007;4:859-66. (Pubitemid 47079624)